Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Intravitreal Aflibercept on Ocular Perfusion – Pilot Study
2016-004608-78Phase 4Completed
- Sponsor
- Kepler Universitätsklinikum
- Start
- Jan 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration and age-related macular degeneration (AMD), sponsored by Kepler Universitätsklinikum. Primary endpoint: Mean blur ratio (LSFG). Started Jan 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2016-004608-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004608-78.